AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21332626 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin
Number of subjects: 0
Study 21332626 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin + Glyburide
Number of subjects: 0
Study 21332626 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin + Pioglitazone
Number of subjects: 0
Study 19231103 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐PBI (38.5 Gy in 10 fractions)
Number of subjects: 25
Study 19231103 — intervention group
Group type: COMPARATOR
Intervention: WBI (50 Gy in 25 fractions)
Number of subjects: 25
Study 17334259 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation
Number of subjects: 13
Study 17334259 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation
Number of subjects: 13
Study 15468395 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion via pain pump catheter for 48 hours
Number of subjects: 16
Study 15468395 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical patients using oral and intravenous pain medications)
Number of subjects: 16
Study 12144204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenderfoot Preemie
Number of subjects: 40
Study 12144204 — intervention group
Group type: COMPARATOR
Intervention: Monolet lancet
Number of subjects: 40
Study 9762795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxaemia (10% O2)
Number of subjects: 17
Study 9762795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic hypoxaemia (10% O2 + high CO2)
Number of subjects: 17
Study 9762795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxaemia (100% O2)
Number of subjects: 17
Study 9762795 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperoxaemia (100% O2 + baseline CO2)
Number of subjects: 17
Study 9762795 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplant subjects
Number of subjects: 17
Study 8086986 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of e4 allele in patients with Alzheimer's disease
Number of subjects: 980
Study 8086986 — intervention group
Group type: COMPARATOR
Intervention: Presence of e4 allele in subjects without dementia
Number of subjects: 980
Study 8086986 — intervention group
Group type: COMPARATOR
Intervention: Subjects with no e4 alleles
Number of subjects: 980
Study 8086986 — intervention group
Group type: COMPARATOR
Intervention: Subjects with one e4 allele
Number of subjects: 980
Study 8086986 — intervention group
Group type: COMPARATOR
Intervention: Subjects with two e4 alleles
Number of subjects: 980
Study 3140562 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1.0 mg i.v. at extubation
Number of subjects: 0
Study 3140562 — intervention group
Group type: COMPARATOR
Intervention: Reference group (thiopentone, alfentanil, nitrous oxide)
Number of subjects: 0
Study 3140562 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA with midazolam
Number of subjects: 0
Study 3140562 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study 31937303 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased urine output (UO) as a continuous variable
Number of subjects: 835
Study 31937303 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased urine output (UO) as a quartile variable
Number of subjects: 835
Study 31937303 — intervention group
Group type: EXPERIMENTAL
Intervention: UO/FI ratio ≤0.5 with increased UO/FI
Number of subjects: 835
Study 31937303 — intervention group
Group type: EXPERIMENTAL
Intervention: UO/FI ratio >0.5
Number of subjects: 835
Study 31937303 — intervention group
Group type: EXPERIMENTAL
Intervention: UO in subgroup with UO/FI ≤0.5
Number of subjects: 835
Study 31937303 — intervention group
Group type: EXPERIMENTAL
Intervention: UO in subgroup with UO/FI >0.5
Number of subjects: 835
Study 31675088 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Connects (FC) program
Number of subjects: 936
Study 31675088 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 936
Study 28144131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice concentrate
Number of subjects: 227
Study 28144131 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 227
Study 25124456 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong/Tai Chi Easy (QG/TCE)
Number of subjects: 87
Study 25124456 — intervention group
Group type: COMPARATOR
Intervention: Sham Qigong (SQG)
Number of subjects: 87
Study 22893105 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (PCPT)
Number of subjects: 0
Study 22893105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (REDUCE)
Number of subjects: 0
Study 22893105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PCPT and REDUCE)
Number of subjects: 0
Study 21205047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) with dose adaptation based on saliva cotinine concentrations
Number of subjects: 310
Study 21205047 — intervention group
Group type: COMPARATOR
Intervention: Standard care with nicotine patches and monthly dose decreases
Number of subjects: 310
Study 18803492 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-selected music
Number of subjects: 80
Study 18803492 — intervention group
Group type: COMPARATOR
Intervention: Silence (control group)
Number of subjects: 80
Study 16540956 — intervention group
Group type: EXPERIMENTAL
Intervention: ivIGMA (1300 mL infused intravenously within a period of 72 hrs)
Number of subjects: 211
Study 16540956 — intervention group
Group type: COMPARATOR
Intervention: Control (human albumin infused according to the same schedule as ivIGMA)
Number of subjects: 211
Study 16540956 — intervention group
Group type: EXPERIMENTAL
Intervention: ivIGMA
Number of subjects: 211
Study 16540956 — intervention group
Group type: COMPARATOR
Intervention: Control (human albumin)
Number of subjects: 211
Study 12716966 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0
Study 10922313 — intervention group
Group type: COMPARATOR
Intervention: Arylane membrane
Number of subjects: 0
Study 8807439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 20 mg b.i.d. for 4 weeks
Number of subjects: 52
Study 8807439 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg b.i.d. for 4 weeks
Number of subjects: 52
Study 8807439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 52
Study 8807439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 1391266 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural porcine surfactant (Curosurf)
Number of subjects: 13
Study 1391266 — intervention group
Group type: COMPARATOR
Intervention: Nontreated control infants
Number of subjects: 13
Study 3926732 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron therapy (mixed neutron-photon fractionated irradiation)
Number of subjects: 98
Study 3926732 — intervention group
Group type: COMPARATOR
Intervention: Photon irradiation
Number of subjects: 98
Study 3926732 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron therapy
Number of subjects: 98
Study 3926732 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 98
Study 31560567 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation intervention (n=18)
Number of subjects: 54
Study 31560567 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration intervention (n=18)
Number of subjects: 54
Study 31560567 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted treatment-as-usual (control) (n=18)
Number of subjects: 54
Study 31852650 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical therapy
Number of subjects: 60
Study 31852650 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy of sepsis (Control)
Number of subjects: 60
Study 28619235 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 742
Study 28619235 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 742
Study 25393889 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 150
Study 25393889 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 150
Study 24597974 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss > 2 kg
Number of subjects: 72
Study 24597974 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance/gain
Number of subjects: 72
Study 21924386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) using an arterial occlusive cuff to one thigh for 5 min followed by deflation for 5 min for 4 cycles
Number of subjects: 8
Study 21924386 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no IPC)
Number of subjects: 8
Study 21924386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 8
Study 19442460 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary-based incentives for smoking-cessation and relapse prevention
Number of subjects: 316
Study 17493777 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal estradiol (7.5 microg/24h)
Number of subjects: 115
Study 17493777 — intervention group
Group type: COMPARATOR
Intervention: No estradiol (Control)
Number of subjects: 115
Study 15135009 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.05 IU/kg)
Number of subjects: 30
Study 15135009 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (15%, 0.5 g/kg)
Number of subjects: 30
Study 15135009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline 0.9%)
Number of subjects: 30
Study 12389654 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine screening for Chlamydia trachomatis and Neisseria gonorrhoeae by PCR
Number of subjects: 212
Study 12389654 — intervention group
Group type: COMPARATOR
Intervention: Non-screening (control group)
Number of subjects: 212
Study 9781472 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (α-tocopherol) treatment (400-1600 IU/day)
Number of subjects: 223
Study 9781472 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (α-tocopherol) treatment
Number of subjects: 223
Study 10147496 — intervention group
Group type: EXPERIMENTAL
Intervention: Two worksite health promotion sessions on responsible drinking
Number of subjects: 199
Study 2908307 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 205
Study 2908307 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 205
Study 2908307 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 100 mg
Number of subjects: 205
Study 2908307 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 15 mg
Number of subjects: 205
Study 2908307 — intervention group
Group type: EXPERIMENTAL
Intervention: All medications
Number of subjects: 205
Study 16291892 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum A toxin (100 U Allergan)
Number of subjects: 86
Study 16291892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 30844842 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mm OCCIs
Number of subjects: 140
Study 30844842 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mm OCCIs
Number of subjects: 140
Study 30844842 — intervention group
Group type: COMPARATOR
Intervention: 3.0 mm SCCI
Number of subjects: 140
Study 30844842 — intervention group
Group type: COMPARATOR
Intervention: 2.0 mm SCCI
Number of subjects: 140
Study 28768781 — intervention group
Group type: EXPERIMENTAL
Intervention: KneeAlign2 system (KA2 group)
Number of subjects: 241
Study 28768781 — intervention group
Group type: COMPARATOR
Intervention: Conventional intramedullary femoral guide (IM group)
Number of subjects: 241
Study 26598177 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cognitive exercise (1 hour daily for 10 days before surgery)
Number of subjects: 264
Study 26598177 — intervention group
Group type: COMPARATOR
Intervention: No preoperative intervention (control group)
Number of subjects: 264
Study 23152480 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Number of subjects: 170
Study 23152480 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard ART without enfuvirtide)
Number of subjects: 170
Study 23152480 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline RNA tropism
Number of subjects: 170
Study 21784533 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day for six weeks
Number of subjects: 93
Study 19906348 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/d
Number of subjects: 296
Study 19906348 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/d
Number of subjects: 296
Study 19906348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 16823725 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 32
Study 16823725 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 32
Study 14638924 — intervention group
Group type: COMPARATOR
Intervention: High-flux dialysis
Number of subjects: 1846
Study 10904025 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant (10 mg IV) coadministered with perindoprilat (1.5 mg IV)
Number of subjects: 12
Study 10904025 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat (1.5 mg IV)
Number of subjects: 12
Study 9519139 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 17 broad spectrum sunscreen cream
Number of subjects: 431
Study 9519139 — intervention group
Group type: COMPARATOR
Intervention: Placebo base cream
Number of subjects: 431
Study 8282427 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/Gantrez dentifrice
Number of subjects: 0
Study 8282427 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/pyrophosphate dentifrice
Number of subjects: 0
Study 8282427 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/zinc citrate dentifrice
Number of subjects: 0
Study 8282427 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (0.8% monofluorophosphate-silica)
Number of subjects: 0
Study 3030387 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 16 mg
Number of subjects: 36
Study 3030387 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg and over
Number of subjects: 36
Study 3030387 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 36
Study 3030387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31731111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg by mouth daily for 90 days
Number of subjects: 120
Study 28712686 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch Surgery (TS) application
Number of subjects: 27
Study 28712686 — intervention group
Group type: COMPARATOR
Intervention: Textbook
Number of subjects: 27
Study 26589187 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal PTSD (high-risk group)
Number of subjects: 68
Study 26589187 — intervention group
Group type: COMPARATOR
Intervention: Maternal PTSD (low-risk group)
Number of subjects: 68
Study 25164452 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient fortified salt
Number of subjects: 0
Study 25164452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 0
Study 25164452 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 21067776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented-EPS
Number of subjects: 20
Study 21067776 — intervention group
Group type: COMPARATOR
Intervention: Cemented-CPS
Number of subjects: 20
Study 20616365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraplet-primed PCR (TP-PCR)
Number of subjects: 213
Study 20616365 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-range PCR (used in combination with TP-PCR)
Number of subjects: 213
Study 18702776 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided clinical reasoning
Number of subjects: 225
Study 18702776 — intervention group
Group type: COMPARATOR
Intervention: Classic case discussions
Number of subjects: 225
Study 15516352 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 5 mg/ml in plain solution
Number of subjects: 40
Study 15516352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg/ml with glucose 50 mg/ml (hyperbaric solution)
Number of subjects: 40
Study 12855328 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended procedure (tip of the colonoscope remained in the rectum)
Number of subjects: 682
Study 12855328 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard procedure)
Number of subjects: 682
Study 12855328 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended procedure
Number of subjects: 682
Study 10596996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcon group (360±80 IU/kg of heparin)
Number of subjects: 57
Study 10596996 — intervention group
Group type: COMPARATOR
Intervention: Control group (300 IU/kg of heparin)
Number of subjects: 57
Study 10596996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcon group
Number of subjects: 57
Study 8619357 — intervention group
Group type: EXPERIMENTAL
Intervention: iobitridol 300
Number of subjects: 68
Study 8619357 — intervention group
Group type: COMPARATOR
Intervention: iopromide 300
Number of subjects: 68
Study 8619357 — intervention group
Group type: COMPARATOR
Intervention: iopamidol 300
Number of subjects: 68
Study 2027802 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous long-acting epinephrine (Sus-Phrine), 0.005 ml per kg before albuterol aerosols
Number of subjects: 43
Study 2027802 — intervention group
Group type: COMPARATOR
Intervention: Albuterol aerosols
Number of subjects: 43
Study 7023861 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.05 mg/kg)
Number of subjects: 12
Study 7023861 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atropine and terbutaline sulfate (0.005 mg/kg)
Number of subjects: 12
Study 7023861 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline sulfate (0.005 mg/kg)
Number of subjects: 12
Study 30840136 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g h-1 glucose-fructose
Number of subjects: 11
Study 30840136 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g h-1 glucose-fructose
Number of subjects: 11
Study 30840136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 28025693 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic herniorrhaphy (LH)
Number of subjects: 41
Study 28025693 — intervention group
Group type: COMPARATOR
Intervention: Open herniorrhaphy (OH)
Number of subjects: 41
Study 26467136 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Port Surgery
Number of subjects: 30
Study 26467136 — intervention group
Group type: COMPARATOR
Intervention: Classical Laparoscopic Cholecystectomy
Number of subjects: 30
Study 23858719 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immune therapy (SIT)
Number of subjects: 40
Study 22563485 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) applied to the occipital poles
Number of subjects: 0
Study 22563485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study 22563485 — intervention group
Group type: COMPARATOR
Intervention: Control measure (overlay suppression)
Number of subjects: 0
Study 20017325 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychological therapy for depression and anxiety during pregnancy (6 sessions, 1.5 hours each)
Number of subjects: 800
Study 20017325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 800
Study 20017325 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychological therapy
Number of subjects: 800
Study 20017325 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 800
Study 17296230 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery
Number of subjects: 400
Study 17296230 — intervention group
Group type: COMPARATOR
Intervention: Manual small-incision cataract surgery (SICS)
Number of subjects: 400
Study 15336297 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (PAR) 20 mg
Number of subjects: 12
Study 15336297 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) 20 mg
Number of subjects: 12
Study 15336297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15279537 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-session Iowa Strengthening Families Program (ISFP)
Number of subjects: 33
Study 15279537 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session Preparing for the Drug Free Years Program (PDFY)
Number of subjects: 33
Study 15279537 — intervention group
Group type: COMPARATOR
Intervention: Minimal-contact control condition
Number of subjects: 33
Study 10601133 — intervention group
Group type: EXPERIMENTAL
Intervention: SR49059 (300 mg oral dose)
Number of subjects: 24
Study 7582278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 750 micrograms twice daily
Number of subjects: 96
Study 7582278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1000 micrograms twice daily
Number of subjects: 96
Study 7582278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 7582278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (both dosages)
Number of subjects: 96
Study 1791718 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g, 1 tablet, 4 times a day for 20 days)
Number of subjects: 82
Study 1791718 — intervention group
Group type: EXPERIMENTAL
Intervention: Venter (1 g, 1 tablet, 4 times a day for 20 days)
Number of subjects: 82
Study 1791718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 1791718 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 82
Study 6972165 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate twice daily for a month)
Number of subjects: 15
Study 6972165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 15
Study 30718577 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 and CPP-ACP nanocomplexes
Number of subjects: 0
Study 30718577 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0